ELVN-001

ENABLE trial. 6/13/25- Presented updated results at EHA'25. 9/3/25- Presented data at SOHO'25. 11/3/25- Present data from ongoing trial at ASH'25 on December 7th. 01/08/26:- Initial Ph1b ENABLE data positive. Ph1 data mid-2026; FDA alignment and ENABLE-2 Ph3 start H2 2026. 03/03/26:- Reported positive initial Ph1b ENABLE data; mid-2026 ENABLE Ph1 data presentation and H2 2026 ENABLE-2 Ph3 initiation expected. 05/07/26:- Reiterated mid-2026 ENABLE Ph1 data update and H2 2026 ENABLE-2 Ph3 initiation with planned FDA interactions. 05/12/26:- Updated ENABLE Ph1 data to be presented at EHA 2026 on June 11, 2026. 06/03/26:- ENABLE Ph1 updated data at EHA 2026 June 11; webcast 8:30 a.m. ET. 06/11/26:- Updated Ph1 ENABLE data at EHA 2026; FDA aligned 80 mg QD; ENABLE-2 Ph3 starts H2 2026.